维得利珠单抗与肿瘤坏死因子拮抗剂治疗克罗恩病的安全性和有效性比较
这项回顾性观察性队列研究(2014年5月至2017年12月)采用倾向评分加权比较维得利珠单抗与肿瘤坏死因子拮抗剂治疗成人克罗恩病的安全性和有效性,共纳入1266例患者(维得利珠单抗组659例)。维得利珠单抗组非感染性严重不良事件风险显著低于肿瘤坏死因子拮抗剂组,但严重感染风险无显著差异;临床缓解、无激素临床缓解和内镜下缓解均无显著差异。
要点
- 维得利珠单抗组非感染性严重不良事件风险显著低于肿瘤坏死因子拮抗剂组(OR 0.072,95%CI 0.012-0.242)。
- 两组严重感染风险无显著差异(OR 1.183,95%CI 0.786-1.795)。
- 临床缓解、无激素临床缓解和内镜下缓解在两组间均无显著差异。
核心结论
- 维得利珠单抗较肿瘤坏死因子拮抗剂治疗的非感染性严重不良事件风险更低,但严重感染风险无显著差异,且达到疾病缓解方面无显著差异。
研究设计与样本
- 回顾性观察性队列研究(2014年5月至2017年12月),采用倾向评分加权比较维得利珠单抗与肿瘤坏死因子拮抗剂(英夫利西单抗、阿达木单抗、赛妥珠单抗)治疗成人克罗恩病,共纳入1266例患者(维得利珠单抗组659例)。
主要发现
- 维得利珠单抗组非感染性严重不良事件风险显著低于肿瘤坏死因子拮抗剂组(OR 0.072,95%CI 0.012-0.242)。
- 两组严重感染风险无显著差异(OR 1.183,95%CI 0.786-1.795)。
- 两组临床缓解无显著差异(HR 0.932,95%CI 0.707-1.228)。
- 两组无激素临床缓解无显著差异(HR 1.250,95%CI 0.677-2.310)。
- 两组内镜下缓解无显著差异(HR 0.827,95%CI 0.595-1.151)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)-antagonist therapy in Crohn's disease (CD). AIM: To compare safety and effectiveness of vedolizumab and TNF-antagonist therapy in adult CD patients. METHODS: Retrospective observational cohort (May 2014-December 2017) propensity score-weighted comparison of vedolizumab vs TNF-antagonist therapy (infliximab, adalimumab, certolizumab) in CD. Propensity scores were weighted for age, prior treatments, disease complications, extent and severity, steroid dependence, and concomitant immunosuppressive drug use. The primary outcome was comparative risk for infections or non-infectious serious adverse events (requiring antibiotics, antivirals, antifungals, hospitalisation, or treatment discontinuation, or resulting in death). Secondary comparative effectiveness outcomes were clinical remission (resolution of CD-related symptoms), steroid-free clinical remission and endoscopic remission (absence of ulcers/erosions). RESULTS: We included 1266 patients (n = 659 vedolizumab). Rates of non-infectious serious adverse events (odds ratio [OR] 0.072, 95% confidence interval [CI] 0.012-0.242), but not serious infections (OR 1.183, 95% CI 0.786-1.795), were significantly lower with vedolizumab vs TNF-antagonist therapy. Safety comparisons for non-infectious serious adverse events remained significant after adjusting for differences in duration of exposure. No significant difference was observed between vedolizumab and TNF-antagonist therapy for clinical remission (hazard ratio [HR] 0.932, 95% CI 0.707-1.228), steroid-free clinical remission (HR 1.250, 95% CI 0.677-2.310) or endoscopic remission (HR 0.827, 95% CI 0.595-1.151). TNF-antagonist therapy was associated with higher treatment persistence compared with vedolizumab. CONCLUSIONS: There was a lower risk of non-infectious serious adverse events, but not serious infections, with vedolizumab vs TNF-antagonist therapy, with no significant difference for achieving disease remission.
引用
- Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther. 2020. PMID: 32656800. doi:10.1111/apt.15921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。